Azacitidine and lenalidomide combination: a novel relapse prophylaxis regimen after allogeneic hematopoietic stem-cell transplantation in patients with acute myeloid leukemia

Azacitidine and lenalidomide combination: a novel relapse prophylaxis regimen after allogeneic hematopoietic stem-cell transplantation in patients with acute myeloid leukemia

IntroductionWhile allogeneic hematopoietic stem cell transplantation (allo-HSCT) can be a curative regimen for acute myeloid leukemia (AML), relapse of AML remains a serious risk post-transplantation. Once relapsed, salvage options are limited and management of AML is difficult. Here we designed a p...

Full description

Bibliographic Details
Main Authors: Yimei Feng, Ting Chen, Yun Zhang, Han Yao, Ping Wang, Lu Wang, Kaniel Cassady, Zhongmin Zou, Yuqing Liu, Lu Zhao, Lei Gao, Xi Zhang, Peiyan Kong
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Immunology
Subjects:
allo-SCT
azacitidine
lenalidomide
maintenance therapy
AML
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1182251/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1182251/full

Similar Items